Physician profile
Raj Gupta
NPI 1831126689
$10,647.08
in general payments reported to CMS, 2019-2025
60 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,607 · 2020: $409 · 2021: $1,047 · 2022: $938 · 2023: $867 · 2024: $3,618 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256 · Travel and Lodging: $1,388 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,256.35 |
| Travel and Lodging | $1,387.73 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $2,422.16 | 2019-2024 | |
| Livanova USA, INC. | $1,757.56 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $614.95 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Eisai INC. | $480.48 | 2019-2025 | |
| Abbvie INC. | $472.14 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $348.88 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $331.80 | 2022-2025 | Vyepti, Rexulti |
| Amgen INC. | $277.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $253.98 | 2019-2024 | Austedo Xr |
| Biogen, INC. | $233.30 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $222.99 | 2019-2025 | Zepbound, Amyvid |
| Allergan, INC. | $221.42 | 2019-2022 | |
| Inspire Medical Systems, INC. | $220.45 | 2024-2025 | Inspire |
| Mdd US Operations, LLC | $165.46 | 2021-2025 | |
| Catalyst Pharmaceuticals, INC. | $152.86 | 2023-2025 | Fycompa |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.